Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Acer Therapeutics Inc. (Nasdaq: ACER) announced its participation in the H.C. Wainwright Global Investment Conference from May 24-26, 2022. The event will feature an on-demand recorded presentation and one-on-one virtual meetings starting at 7:00 am ET on May 24. Acer focuses on therapies for serious, rare diseases with unmet medical needs, including programs like ACER-001 for metabolic disorders and ACER-801 for induced vasomotor symptoms. The company aims to develop treatments with favorable safety profiles and accelerated regulatory paths.
- None.
- None.
NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually present at, and participate in, the H.C. Wainwright Global Investment Conference May 24-26, 2022.
| Format: | On-demand recorded virtual presentation and one-on-one virtual meetings |
| Date: | On-demand presentation available beginning at 7:00 am ET, May 24, 2022 |
| Webcast: | https://journey.ct.events/view/2b639762-a11f-4570-8694-012c299884ce |
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.
Corporate and IR Contact:
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com
FAQ
What is the date of Acer Therapeutics' presentation at the H.C. Wainwright Global Investment Conference?
What type of presentation will Acer Therapeutics provide at the conference?
What is the starting time for Acer's presentation at the conference?
Where can I find the webcast link for Acer's presentation?
What is the focus of Acer Therapeutics?
